| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.57% | 68.86% | 67.35% | 68.54% | 66.16% | 73.50% | 75.54% | 73.81% | 71.87% | 67.41% | 59.32% | 51.30% |
| Operating Margin | -7.68% | -19.52% | -25.40% | -27.69% | -30.96% | -16.47% | -25.52% | -29.61% | -27.68% | -24.32% | -59.85% | -67.89% |
| EBITDA Margin | -4.91% | -16.02% | -22.10% | -24.43% | -27.92% | -13.87% | -23.91% | -28.07% | -26.06% | -23.43% | -58.49% | -66.78% |
| Net Margin | -5.96% | -19.14% | -25.05% | -28.27% | -31.40% | -16.53% | -25.43% | -32.78% | -29.87% | -32.62% | -63.09% | -72.79% |
| Current Ratio | 4.63 | 5.82 | 2.15 | 3.24 | 3.48 | 5.75 | 3.32 | 3.52 | 5.72 | 8.98 | 3.74 | — |
| Quick Ratio | 4.48 | 5.70 | 2.02 | 3.07 | 3.36 | 5.67 | 3.24 | 3.45 | 5.64 | 8.87 | 3.61 | — |
| Debt / Equity | 4.68 | 7.93 | 0.17 | 0.15 | 0.08 | 0.10 | 0.26 | 0.64 | 0.43 | 0.35 | -0.30 | — |
| ROE | -29.17% | -124.62% | -58.74% | -48.44% | -36.26% | -12.83% | -40.30% | -88.71% | -36.98% | -22.58% | 22.43% | — |
| ROA | -4.37% | -12.16% | -28.49% | -25.91% | -21.89% | -8.56% | -17.82% | -40.33% | -22.10% | -15.13% | -60.20% | — |
| Asset Turnover | 0.73 | 0.64 | 1.14 | 0.92 | 0.70 | 0.52 | 0.70 | 1.23 | 0.74 | 0.46 | 0.95 | — |
| Book Value / Share | 4.77 | 2.91 | 6.88 | 8.02 | 9.53 | 12.31 | 5.36 | 2.28 | 3.52 | 17.51 | -73.85 | — |
iRhythm Technologies Inc. is a leading digital healthcare company that develops and commercializes wearable biosensors and cloud-based analytics for detecting, predicting, and preventing cardiac diseases. Its flagship Zio platform features an FDA-cleared, CE-marked, wire-free patch-based biosensor that records up to 14 days of continuous electrocardiogram (ECG) data, paired with proprietary AI-driven software that analyzes millions of heartbeats to deliver actionable clinical insights for diagnosing arrhythmias more efficiently than traditional methods. The Zio system supports ambulatory cardiac monitoring, including long-term continuous monitoring (LTCM) and mobile cardiac telemetry, enabling faster detection of conditions like atrial fibrillation across diverse patient populations, including those with cardio-kidney-metabolic diseases. iRhythm Technologies Inc. serves clinicians through services that emphasize patient-centric design, such as home self-application, high analyzable ECG time, and real-world evidence from large-scale studies. Operating in the U.S. core market, innovative channels, and internationally, the company plays a key role in advancing ambulatory ECG monitoring and data-driven cardiac diagnostics.